- Home
- CHY vs OPK Comparison
CHY vs OPK Comparison
Compare CHY & OPK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CHY | OPK |
|---|---|---|
| Founded | 2003 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 921.2M |
| IPO Year | N/A | 2011 |
Fundamental Metrics
Financial Performance| Metric | CHY | OPK |
|---|---|---|
| Price | $12.93 | $1.29 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $1.60 |
| AVG Volume (30 Days) | 217.9K | ★ 2.3M |
| Earning Date | 01-01-0001 | 04-28-2026 |
| Dividend Yield | ★ 10.11% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $606,879,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $4.24 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.32 | $0.98 |
| 52 Week High | $13.11 | $1.60 |
Technical Indicators
Market Signals| Indicator | CHY | OPK |
|---|---|---|
| Relative Strength Index (RSI) | 59.47 | 71.83 |
| Support Level | $11.28 | $1.28 |
| Resistance Level | $13.11 | $1.42 |
| Average True Range (ATR) | 0.28 | 0.04 |
| MACD | -0.04 | 0.02 |
| Stochastic Oscillator | 80.00 | 93.33 |
Price Performance
Historical ComparisonAbout CHY Calamos Convertible and High Income Fund
Calamos Convertible & High Income Fund is a diversified, closed-end management investment company. Its objective is to provide total return through a combination of capital appreciation and current income. The firm invests in a diversified portfolio of convertible securities and high-yield securities.
About OPK OPKO Health Inc.
OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Its segments include pharmaceutical and diagnostics. The Pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. The Diagnostics segment consists of clinical and genomics laboratory operations through BioReference and point-of-care operations. It generates the majority of its revenue from the Diagnostics segment.